Research raises ‘valid questions’ about Amgen’s Repatha, says Barclays

After research published in BMJ questioned "inconsistencies" between the information in the Clinical Study Report and that in the 2017 primary trial results publication for the FOURIER trial of evolocumab, Barclays analyst Carter Gould said he suspects this recent publication "will be the first many have heard of these arguments," which in his view "raise a number of valid questions." The analyst, who sees this analysis representing "an unwelcome new narrative around a core franchise," thinks this could drive increased uncertainty around longer-term Repatha estimates, he tells investors. Gould keeps an Underweight rating and $234 price target on Amgen shares.